Keyword: Otsuka Pharmaceutical

Shire could fill Takeda's gap of late-stage assets; GSK lays off 1,000 as a Bangladesh plant nears closure; Laekna gets two Novartis cancer drugs.

Biogen and Eisai's anti-amyloid candidate shows promise; Otsuka signs two M&A deals; Samsung BioLogics faces criminal probe over Biogen JV agreement.

Though she has spent most of her career in oncology, Deborah Dunsire, M.D., says she doesn't plan to expand Lundbeck outside of neuroscience.

Pfizer exits a JV with China's Hisun Pharma, FDA approved the first digital medicine, and Astellas was added to a charity donation probe.

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Big Pharma companies largely enjoyed a nice first-half jump in value.

Orphan drug sales have nearly doubled since 2008, a trend set to continue through 2022 as companies increasingly focus on rare disease meds.

Sun's U.S. sales dropped 34% last quarter, Grail is merging with Hong Kong-based Cirina, Shanghai-based InventisBio raised $19 million in series B.

A month after Daiichi Sankyo announced plans for a major investment in cancer drug production, Japanese compatriot Otsuka said it is planning to do the same thing.

Merck's HPV shot Gardasil won approval in China, Lupin's Q4 sales in North America fell 13%, and China’s CANbridge gained a $25M series B.